@targetedonc | Linktree
Linktree. Make your link do more.
Linktree. Make your link do more.
The FDA is considering a subcutaneous nivolumab formulation for various solid tumors based on promising data from the phase 3 CheckMate -67T trial. A target…
Non-muscle invasive bladder cancer treatment with TAR-210 demonstrated safety and clinical activity in FGFR-altered high- and intermediate-risk patient groups.
Combination therapy with nivolumab and gemcitabine-cisplatin showed promising results in treating metastatic urothelial carcinoma with significantly improved overall survival and progression-free survival rates.
May 6, 2024, is Melanoma Monday. In this article, Niroshana Anandasabapathy, MD, PhD, explores how advancements in detection and treatment are improving the fight against…
The final segment explores the potential role of axatilimab, a novel agent, in the management of refractory cGvHD, highlighting its mechanism of action and potential…
Treatment with enzalutamide alone and with leuprolide delivered higher rates of undetectable PSA levels compared with leuprolide alone in patients with castration-sensitive prostate cancer.
Roger Li, MD, discusses what the future may hold for the use of TAR-210 for the treatment of patients with intermediate-risk non-muscle-invasive bladder cancer with…
Combination nivolumab and nab-paclitaxel may be a safe and effective treatment for patients with muscle-invasive bladder cancer.
The addition of PSMA-PET imaging to multi-parametric MRI was associated with an improvement in the detection of clinically significant prostate cancer.
Nadofaragene firadenovec maintained its durable clinical activity at 5 years in patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer.